{"entity":{"id":"nct07504263","kind":"trial","name":"Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies","aka":[],"tldr":"A phase 1/2 trial in pancreatic cancer, run by Recurv Pharma Inc, not yet recruiting.","summary":"Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies is a phase 1/2, interventional study registered as NCT07504263 by Recurv Pharma Inc, with a registry enrolment figure of 66 participants, started 2026-04-23 and due to reach its primary completion in 2027-12-01. Interventions recorded: RP-001. Conditions listed: Advanced Malignancies; Oncology; Colorectal Cancer; Pancreatic Cancer; Cancer. Primary outcome: To characterize the safety and tolerability of RP-001 administered as monotherapy.. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07504263","url":"https://clinicaltrials.gov/study/NCT07504263"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07504263","phase":"1/2","setting":"An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of RP-001 in Participants With Advanced Malignancies","sponsor":"Recurv Pharma Inc","enrolled":66,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07504263/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}